Form 8-K - Current report:
SEC Accession No. 0001213900-25-024114
Filing Date
2025-03-14
Accepted
2025-03-14 16:02:25
Documents
15
Period of Report
2025-03-13
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0234488-8k_longeveron.htm   iXBRL 8-K 38599
2 LETTER TO SECURITIES AND EXCHANGE COMMISSION FROM MARCUM LLP DATED MARCH 14, 202 ea023448801ex16-1_longeveron.htm EX-16.1 2160
6 GRAPHIC ex16-1_001.jpg GRAPHIC 15179
  Complete submission text file 0001213900-25-024114.txt   239663

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lgvn-20250313.xsd EX-101.SCH 3021
4 XBRL LABEL FILE lgvn-20250313_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE lgvn-20250313_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0234488-8k_longeveron_htm.xml XML 3798
Mailing Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136
Business Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136 305-302-7158
Longeveron Inc. (Filer) CIK: 0001721484 (see all company filings)

EIN.: 472174146 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40060 | Film No.: 25739866
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)